Brookline analyst Kemp Dolliver downgraded Y-mAbs Therapeutics (YMAB) to Hold from Buy with an $8.60 price target after the company agreed to be acquired by SERB Pharmaceuticals for $8.60 per share in cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on YMAB:
- Y-mAbs Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
- Y-mAbs Therapeutics downgraded to Hold from Buy at Clear Street
- Y-mAbs Therapeutics downgraded to Hold from Buy at JonesResearch
- Palantir reports Q2 beat, Caterpillar posts mixed results: Morning Buzz
- Y-mAbs Therapeutics downgraded to Neutral from Outperform at Wedbush